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Abstract
Background—The true benefit of pharmacological intervention to improve cognition in
schizophrenia may not be evident without regular cognitive enrichment. Clinical trials assessing
the neurocognitive effects of new medications may require engagement in cognitive remediation
exercises to stimulate the benefit potential. However, the feasibility of large-scale multi-site
studies using cognitive remediation at clinical trials sites has not been established.
Methods—Patients with DSM-IV schizophrenia from nine sites were randomized to a cognitive
remediation condition that included the Posit Science Brain Fitness auditory training program with
weekly NEAR ‘bridging groups,’ or a control condition of computer games and weekly healthy
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lifestyles groups. Patients were expected to complete 3–5 one-hour sessions weekly for 40
sessions or 12 weeks, whichever came first.
Results—The primary outcomes were feasibility results as measured by rate of enrollment,
retention, and completion rate of primary outcome measures. Within the 3-month enrollment
period, 53 of a projected 54 patients were enrolled and 47 completed the study. Thirty-one patients
completed all 40 sessions and all patients completed all primary outcome measures. Preliminary
efficacy results indicated that after 20 sessions, patients in the cognitive remediation condition
demonstrated mean MCCB composite score improvements that were 3.7 (95% CI: 7.34, 0.05) T-
score points greater than in patients in the computer games control group (F=4.16, df=1,46,
p=0.047). At the end of treatment, a trend favoring cognitive remediation was not statistically
significant (F=2.26, df=1,47, p=0.14).
Discussion—Multi-site clinical trials of cognitive remediation using the Posit Science auditory
training program with the NEAR method of weekly bridging groups in traditional clinical sites
appear feasible.
INTRODUCTION
Neurocognitive impairment affects almost all patients with schizophrenia1, ranges from
moderate to severe,2 and is strongly correlated with functional outcomes3,4. Current
antipsychotic treatment does little to improve cognitive impairment5,6. While several studies
are ongoing to explore new treatments for cognitive impairment in schizophrenia, no
pharmacologic approaches to improve cognition have yet been successful7–9.
Many patients who enroll in pharmacologic enhancement studies have little daily cognitive
stimulation. It is possible that experimental pharmacologic interventions offer minimal or no
benefit when patients are evaluated in this context. Analogous to the need for physical
exercise in an individual who takes steroids to increase muscle mass, schizophrenia patients
in pharmacological intervention trials may require systematic cognitive training to
“exercise” any newfound cognitive potential that they may have acquired from drug
treatment10.
Cognitive remediation has been defined as “a behavioral training based intervention that
aims to improve cognitive processes (attention, memory, executive function, social
cognition or metacognition) with the goal of durability and generalization” (Cognitive
Remediation Experts Workshop, April, 2010). This area of work is rapidly evolving with
many methodological barriers and potential advances. Cognitive remediation may provide
an excellent platform for enriching the cognitive environment of patients engaged in
pharmacologic trials to improve cognition11. Several studies and meta-analyses suggest that
cognitive remediation produces medium effect size improvements in cognitive performance
and, when combined with psychiatric rehabilitation, also improves functional outcomes12,13.
Patients find these programs to be enjoyable and engaging, and they have been linked with
increases in participant self-esteem14. Previous cognitive remediation trials have reported
significant effects12–14, including those studies that have tested the Posit Science auditory
module compared to a control condition of computer games15–17.
Ongoing treatment with cognitive remediation may thus provide schizophrenia patients with
the necessary cognitive enrichment and motivation to demonstrate the true potential of
effective cognitive enhancement with pharmacologic intervention. However, it is not clear
whether a cognitive remediation intervention could be successfully employed in the large
multi-site clinical trials that are designed to assess drug safety and efficacy. Most of the
cognitive remediation studies performed to date in patients with schizophrenia have been
implemented at single sites with highly trained research personnel and methods developed at
Keefe et al. Page 2













those sites; thus the generalizability of these methods to research sites with limited cognitive
remediation experience is not well established.
The goal of this study was to assess the feasibility of implementing a cognitive remediation
program in a network of sites that do not specialize in this area of research with the
following aims: 1. Determine the feasibility of training staff to provide evidence-based
cognitive remediation to patients with schizophrenia in a set of clinical sites without
substantial cognitive remediation experience but with clinical trials experience. 2. Determine
the feasibility of conducting a controlled, randomized clinical trial to test the effectiveness
of cognitive remediation for individuals with schizophrenia or schizoaffective disorder. 3.
Determine if a cognitive remediation protocol can be implemented with a high level of
protocol adherence by sites and low attrition and good treatment adherence by patients. We
also provide preliminary multi-site efficacy data on the effect of a cognitive remediation
program on neurocognition and related outcomes.
METHODS
Patients and Sites
Nine sites from the Schizophrenia Trials Network, which was originally created to conduct
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial,
were involved in the study. Seven of the sites had no previous experience with cognitive
remediation trials. Each site was asked to enroll six patients with chronic DSM-IV
schizophrenia over the course of 3 months, estimating a reasonable rate of recruitment for a
large-scale efficacy trial. A total of 53 patients were entered into the study. Patients were
required to: be 18–55 years of age; have Positive and Negative Syndrome Scale (PANSS)18
Hallucinatory Behavior, Unusual Thought Content, and Conceptual Disorganization ratings
of no greater than moderately severe (≤ 5), have learned English before age 12; able to
complete the MATRICS Consensus Cognitive Battery (MCCB)19 at the baseline
assessment; obtain a raw score of 37 or greater on the Wide Range Achievement Test,
Reading subtest, 3rd edition (WRAT-3)20 to establish minimum reading level (sixth grade)
and estimated premorbid IQ; and be able to state specific goals relevant to the intervention
that they would like to achieve. Patients were excluded from participating in the study if
they met any of the following criteria: psychiatric hospitalization in the 8 weeks prior to
randomization; adjustments in antipsychotic treatment in the 4 weeks prior to
randomization; current regular use of an anticholinergic medication; DSM-IV diagnosis of
alcohol or substance (other than nicotine) abuse within the last month or dependence within
the last 6 months; history of mental retardation or pervasive developmental disorder; or
other neurological disorder. IRB approval for the protocol was obtained at all sites. Informed
consent was obtained for all patients.
Treatments—The program was based upon suggestions from an NIMH Working Group
on multi-site cognitive remediation methods10. It was designed to be completed over eight
weeks, and consisted of 40 hours of computerized cognitive remediation training or control
computer games, and 5 hours of group sessions. Patients were permitted up to 12 weeks to
complete the 40 hours of training. For each of the three assessment visits, patients received
$20 to help compensate for effort and for transportation costs. To help pay for travel to
receive cognitive remediation or the control intervention for this research study, patients
received limited reimbursement ($5) for transportation costs.
Cognitive Remediation
1. Posit Science Brain Fitness Auditory Training: Patients randomized to the cognitive
remediation group received the computerized Posit Science Brain Fitness auditory training
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program, which has demonstrated successful results in schizophrenia15,16. This program
targets cognitive ability hierarchically in an adaptive design, with repeated exercises aimed
at lower cognitive levels (e.g. auditory perception) before advancing to more complex
cognitive constructs such as verbal memory21. Performance is rewarded through the use of
novel and amusing visual and auditory embellishments, animated graphics, and an
accumulation of points for each successful trial.
2. Bridging Groups: To help patients apply their cognitive skills to their everyday
functioning, study patients receiving the auditory training cognitive remediation program
also attended ‘bridging groups’ that met every week. The goals of these groups were to
teach patients how to apply newly acquired cognitive skill to everyday tasks, promote group
identity, and promote socialization, as conducted in the Neuropsychological Educational
Approach to Remediation, or NEAR, program22. These bridging groups were very
structured with detailed manuals. Group leaders were trained and certified by the developer
of NEAR (AM), who also supervised the leaders to assure fidelity with the manual.
Control Intervention: A control condition was included to determine the effects of the
randomization process and randomized treatment on recruitment, informed consent,
retention, patient burden, maintenance of blinded conditions for assessing outcomes, and to
control for nonspecific treatment effects, such as supportive interactions with research
personnel, reimbursements, experience with computers and computer activities, and general
engagement of attentional systems.
1. Computer Games: Patients in this condition played enjoyable computer games for the
same number of hours as active training patients and received the same amount of contact
with personnel as the experimental group. Patients used 10 computerized games selected and
studied by Fisher et al15.
2. Healthy Lifestyles Groups: To control for possible general benefits of group
participation, study patients receiving the control condition received a healthy lifestyles
group developed by Ganguli and colleagues23.
Randomization and Blinding: Each site randomly assigned three patients to cognitive
remediation and three patients to the computer games control group. Treatments were open-
label, but cognitive testers were blinded to treatment assignments. The success of the
blinding procedures was evaluated as an outcome measure in this feasibility study.
Feasibility Outcomes: The key indicators to evaluate the feasibility of this study were: rate
of enrollment per site and overall, retention of patients in the trial, number of sessions
completed during the course of the trial, blinding effectiveness, and completion rate of
primary outcome measures.
Key Efficacy Outcomes: All efficacy outcomes were evaluated at midpoint (after 20 hours
of participation in the assigned intervention, no more than 6 weeks post randomization) and
end of study (after 40 hours or 12 weeks of participation in the assigned intervention,
whichever came first).
Auditory Frequency Discrimination Task: The most basic of the auditory training exercises
requires users to make gradually more difficult distinctions between frequency modulation
(FM) “sweeps” of auditory stimuli increasing or decreasing in frequency as the sweeps
become progressively faster and are separated by shorter interstimulus intervals. As a
positive control for task learning, patients’ performance on this task was determined in both
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treatment conditions. The outcome measure for this task was the shortest stimulus duration
and inter-stimulus interval (which were equal to each other) for trials where patients were
able to perform the task at 67% accuracy15.
MCCB: The MATRICS Consensus Cognitive Battery (MCCB) was used to assess cognitive
functioning in each of seven domains. T-scores are created for each cognitive domain and an
overall composite score, which was the primary efficacy outcome.
Secondary Outcomes: The University of California, San Diego Performance Based Skills
Assessment, 2nd Edition (UPSA-2)24 is a performance-based measure of the extent to which
patients are capable of performing specific functional living skills such as household chores,
communication, finance, transportation, and planning recreational activities25.
The Cognitive Assessment Interview (CAI)26 is a 10-item interview-based measure of
cognitive function that incorporates ratings from 3 primary sources- subject, informant,
interviewer. The presence of an informant interview was requested but not required.
Additional measures included: the Positive and Negative Symptom Scale (PANSS)27 was
the primary assessment instrument for psychopathology 27 the Clinical Global Impression
Scale (CGI-S)28 rating severity of psychopathology; the Specific Levels of Functioning
Scale (SLOF)29 measuring function in the areas of self-maintenance, social functioning, and
community living skills; the Rosenberg Self-esteem scale30; the Intrinsic Motivation
Inventory-Schizophrenia Research (IMI-SR) scale31; and the Perceived Competency Scale
(PCS)32. The overall study methodology quality was measured with the Clinical Trial
Assessment Measure, a 15-item reliable and valid scale (range 0–100) of trial methodology
for psychological treatment studies33.
Data Analysis
The primary outcome for this trial was determination of the feasibility of conducting a
multisite trial using cognitive remediation. Additional key outcomes were the completion
rate of the primary and secondary outcome measures.
Exploratory efficacy analyses assessed whether there were significant changes after 20
sessions, which was the midpoint of the treatment schedule, and at endpoint, beyond
expected practice effects (0.2 SDs) in the composite scores from the MCCB34. The data
were analyzed using a mixed model approach to repeated measures using change from
baseline to each post-baseline time point as the response, baseline as a covariate, and
treatment, visit, and treatment-by-visit interactions as the predictors. Exploratory analyses
were performed using the same methodology for all MCCB subscales and the other
outcomes.
RESULTS
Demographic and clinical characteristics are described in Table 1. The two treatment groups
did not differ at baseline on any of the 17 clinical or cognitive outcome measures except the
Perceived Competency Scale (P<.02), which would not have been statistically significant if
corrected for multiple comparisons. The baseline, session 20 and end of treatment values for
all outcomes are presented in Table 2.
Feasibility
The Consort Figure (figure 1) describes the sample sizes for each treatment arm. Our stated
goal was for 8 of 9 chosen sites to participate in the trial and for each site to enroll 6
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patients. All nine sites participated and 8 of them enrolled 6 patients with one site enrolling
5. Of the 53 patients in the study, 47 met criteria for study completion, 25 in the cognitive
remediation group and 22 in the computer games control group. Thirty-one patients (16 in
the cognitive remediation condition and 15 in the control condition) completed all 40
sessions, and 16 patients completed fewer than 40 sessions in 12 weeks of treatment. Of
these 16 patients, 9 patients in the cognitive remediation group completed a mean of
24.1(SD=7.5) sessions, and 7 patients in the control group completed a mean of 30.0
(SD=5.42) sessions in 12 weeks. Of the 6 patients who did not complete the study, 2 were
not willing to maintain the time commitment and 4 withdrew for unspecified reasons
Study Methodology Quality
The overall study quality as rated by the Clinical Trials Assessment Measure was 87, which
is equal to the top score given by Wykes et al17 in their review of 40 cognitive remediation
trials where the mean Clinical Trials Assessment Measure rating was 57.4(SD 12.3).
Outcome Measure Completion
All patients completed all MCCB tests at all time points. No more than three patients were
missing data on any of the secondary outcome measures, including all three visits. All
patients had interviewer ratings for the CAI; informant interview data were missing for 8,
13, 14 patients at baseline, 20 sessions, and end of study respectively for the cognitive
remediation group and for 10, 11, 12 patients at those time points for the control group.
Blinding effectiveness
The blinding procedures were very effective. All cognitive testers completed a form asking
them to estimate whether they were unblinded about patients’ treatment condition. In two
cases, one in each treatment condition, testers estimated “definite” unblinding, and both
reports were correct. In 15 additional cases, testers estimated “possible” unblinding.
However, less than 50% of those estimates were correct, which was less than chance. In nine
cases, testers were reasonably certain that a patient was receiving the cognitive remediation,
but in only 4 of those cases was the tester was correct. In 6 cases the tester was reasonably
certain that a patient was receiving the control intervention, but in only 3 of those cases was
the tester correct.
Efficacy Analyses
Auditory Frequency Discrimination Task—Patients receiving the cognitive
remediation intervention had substantial mean improvements on the auditory discrimination
task (see Table 2), which were significantly greater than in patients in the control condition,
who did not improve during the course of the study. This indicates that patients in the
cognitive remediation group significantly improved their psychophysical efficiency in
discriminating rapidly presented auditory FM sweeps, while control condition patients did
not.
MCCB—After 20 weeks, patients receiving the cognitive remediation treatment condition
had MCCB composite scores adjusted for baseline of 32.7 compared to 29.0 for patients
receiving the control condition (F=4.16, df=1,46 p=0.047; see Table 2). This mean change
of 3.7 T-score points had a 95% confidence interval of 7.34, 0.05. At the end of treatment,
patients receiving cognitive remediation had MCCB composite scores adjusted for baseline
of 32.4 compared to 29.7 for those in the control condition (F=2.26, df=1,47, p=0.14; mean
change = 2.73; 95% CI: 6.39, 0.93). Post hoc analyses suggested that the MCCB domains
contributing most strongly to improvement in the cognitive remediation group at the 20
session point were verbal learning (p<.05), social cognition, and reasoning and problem-
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solving (p’s<.10). In patients receiving cognitive remediation, improvement in the auditory
frequency discrimination task was not correlated with changes in the MCCB composite
score or its component domains (all r’s <0.31; all P’s >.14).
Additional Outcomes—There were no significant treatment-related differences on any of
the secondary outcome measures (Table 2).
DISCUSSION
This study assessed the feasibility of conducting a randomized and blinded multi-site trial
using a computerized auditory cognitive remediation intervention with weekly bridging
groups compared to a control condition of computer games paired with healthy lifestyles
weekly group meetings. The burden on patient treatment and assessment was considerable,
with a 40-session target over the course of 8–12 weeks, and a large battery of clinical and
cognitive assessments at baseline, midpoint, and endpoint. In terms of training, enrollment,
patient engagement, and study completion, multi-site trials of cognitive remediation using
these active and control interventions appear to be feasible, supporting large-scale efficacy
trials of cognitive remediation and the use of cognitive remediation as a potential platform
for large-scale drug trials. All sites were able to train testers and cognitive remediation
specialists to the satisfaction of the intervention developers. Further, there were no missing
cognitive measures on the MCCB, and almost no missing data on the clinical outcomes. The
retention rate was very high, with 25 of 27 patients (93%) completing the cognitive
remediation arm of the study. This rate is comparable to previously published single-site
studies using similar methodologies13,15, and the average retention rate of 89% reported in
Wykes’ meta-analysis of 40 studies17. This retention rate is also consistent with similarly
sized government-funded trials assessing the effects of pharmacologic interventions to
improve cognition in schizophrenia7. The sites in this study were from academic medical
centers, and it is not clear whether such encouraging results would be replicated in non-
academic industry trials. It is also not clear how these results would generalize to other
cognitive remediation interventions. However, it appears that the requirement of this
cognitive remediation intervention or a similar one in a drug trial for cognition in
schizophrenia is unlikely to significantly affect recruitment, retention, or the completion of
the study data set.
Although the intention of this study was not to test the efficacy of the cognitive remediation
intervention, it is noteworthy that patients randomized to this condition demonstrated
significant improvement in the FDA-recommended cognitive outcome, the MCCB
composite score, after 20 sessions of treatment. This amount of benefit is consistent with
previous single-site studies15, and similar to that obtained by McGurk et al12 with a different
cognitive remediation package and within 0.1 effect size units of the mean improvement
reported in the recent meta-analysis of Wykes et al17. However, in the current study there
was not additional benefit to the MCCB at the endpoint of this study. Due to an enrollment
and study completion deadline for this project, patients were given only 12 weeks to
complete the 40 sessions, which may not have been sufficient time to gain the maximal
benefit of treatment. It is possible that since 9 of the 25 patients did not receive the entire 40-
session intervention, the efficacy of the cognitive remediation was reduced. Patients in the
auditory training cognitive remediation group demonstrated robust improvement in the
auditory frequency discrimination task at 20 sessions, but no additional improvement by the
end of the study. Little is known about the ideal or minimal dose, frequency, and time course
of cognitive remediation treatment response, which may differ across individuals10,35–37,
and these issued need to be examine in future studies.
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Because this was a feasibility and pilot study, it used a small sample size. However, the
effect size for cognitive improvement with the auditory training intervention coupled with
NEAR bridging groups is consistent with potential significant benefit for patients given
sufficient statistical power to test this hypothesis. These results and the clear feasibility of
the study design in a multi-site trial provide positive proof-of-concept empirical evidence
that two new directions in clinical trial design are possible and worthy of investigation. First,
they suggest that a large well-powered multi-site trial for assessing the true efficacy of
cognitive remediation interventions is feasible. Further, they suggest that drug trials that aim
to provide an enriched cognitive environment for patients can successfully implement
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• Cognitive remediation interventions improve cognitive performance in patients
with schizophrenia
• These interventions can be implemented at research and clinical sites without
previous experience or specific expertise
• Clinical trials assessing the efficacy of new drugs targeting cognition in
schizophrenia can feasibly use cognitive remediation to enrich the cognitive
lives of patients in these trials
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CRSTN Pilot Study CONSORT Chart
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Table 1
CRSTN Demographic Data
Variable Mean (SD) or Number (n = 53)
Age, y, mean (SD) 37 (10.27)
Total Years Education, mean (SD) 13.49 (2.24)
WRAT Reading Scores, mean (SD) 48.5 (5.31)
Patient’s education level
 ≥ High School Education 46










 Previously married* 8
 Never married 41
Living Status
 Independent living 42
 Minimally-structured living 6
 Moderately-structured living 5
*
Includes separated, divorced, and widowed
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